Bevacizumab as first-line therapy for glioblastoma

Future Oncology

Volumn 8, Issue 8, 2012, Pages 929-938

  Piccioni, David ^a   Lai, Albert ^a   Nghiemphu, Phioanh ^a   Cloughesy, Timothy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bevacizumab; first line therapy; newly diagnosed glioblastoma; pseudoresponse

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CILENGITIDE; CORTICOSTEROID; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLACEBO; SERUM ALBUMIN; TALAMPANEL; TEMOZOLOMIDE;

ADJUVANT THERAPY; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CONTRAST ENHANCEMENT; CONVULSION; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; INTESTINE PERFORATION; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SEX DIFFERENCE; THROMBOCYTOPENIA; TUMOR GROWTH; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; GLIOBLASTOMA; HUMANS; TREATMENT OUTCOME;

EID: 84865214312     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.81     Document Type: Article

References (36)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
2. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345(8956), 1008-1012 (1995).
3. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien) 148(3), 269-275; discussion 275 (2006).
4. Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
5. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
6. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
7. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
8. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol. 62(5), 779-786 (2008).
9. Moen MD. Bevacizumab: in previously treated glioblastoma. Drugs 70(2), 181-189 (2010).
10. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288(1), 371-378 (1999).
11. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 7(3), Abstract 342 (2005).
12. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 28(11), 1779-1802 (2006).
13. Chinot OL, De La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 28(4), 334-340 (2011).
14. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7(4), 335-345 (2004).
15. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841-844 (1993).
16. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
17. Narayana A, Gruber D, Kunnakkat S et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 116(2), 341-345 (2012).
18. Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110(1), 173-180 (2009).
19. Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res. 17(12), 4119-4124 (2011).
20. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16(8), 2443-2449 (2010).
21. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J. Neurosurg. 47(3), 329-335 (1977).
22. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8(7), 1277-1280 (1990).
23. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr. Oncol. Rep. 13(1), 50-56 (2011).
24. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28(11), 1963-1972 (2010).
25. Brandsma D, Stalpers L, Taal W, Sminia P, Van Den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9(5), 453-461 (2008).
26. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26(13), 2192-2197 (2008).
27. Brandsma D, Van Den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr. Opin Neurol. 22(6), 633-638 (2009).
28. Prados M, Cloughesy T, Samant M et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 13(1), 143-151 (2011).
29. Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol. 27(25), 4155-4161 (2009).
30. Butowski N, Chang SM, Junck L et al. A Phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J. Neurooncol. 91(2), 175-182 (2009).
31. Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610-5617 (2008).
32. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65(3), 671-680 (2005).
33. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 10(3), 355-360 (2008).
34. Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol. 106(1), 121-125 (2012).
35. Narayana A, Golfinos JG, Fischer I et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 72(2), 383-389 (2008).
36. Vredenburgh JJ, Desjardins A, Kirkpatrick JP et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 58-66 (2010).